288 related articles for article (PubMed ID: 7012258)
1. Dexamethasone in the treatment of nausea and vomiting from cancer chemotherapy.
Winokur SH; Baker JJ; Lokey JL; Price NA; Bowen J
J Med Assoc Ga; 1981 Apr; 70(4):263-4. PubMed ID: 7012258
[No Abstract] [Full Text] [Related]
2. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy.
Markman M; Sheidler V; Ettinger DS; Quaskey SA; Mellits ED
N Engl J Med; 1984 Aug; 311(9):549-52. PubMed ID: 6379459
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
[TBL] [Abstract][Full Text] [Related]
4. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced nausea and vomiting.
Hesketh PJ
N Engl J Med; 2008 Jun; 358(23):2482-94. PubMed ID: 18525044
[No Abstract] [Full Text] [Related]
6. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Andersson H; Hansen O; Sørensen BT; Räisänen I
Anticancer Drugs; 1995 Feb; 6 Suppl 1():31-6. PubMed ID: 7749168
[TBL] [Abstract][Full Text] [Related]
7. Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban Group.
Van Belle SJ; Cocquyt VF; Bleiberg H; Canon JL; Buyse M; Hulstaert F; De Witte M; De Keyser P; Westelinck K
Anticancer Drugs; 1995 Feb; 6 Suppl 1():22-30. PubMed ID: 7749166
[TBL] [Abstract][Full Text] [Related]
8. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
[TBL] [Abstract][Full Text] [Related]
9. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
10. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
11. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
12. Prevention of delayed emesis caused by chemotherapy.
Harmon D; O'Brien B
N Engl J Med; 2000 Sep; 343(12):889; author reply 889-90. PubMed ID: 11001695
[No Abstract] [Full Text] [Related]
13. The value of dexamethasone when added to combination drug therapy in the prevention of cisplatin-induced nausea and vomiting, evaluated by time-lapse video technology.
Rhinehart SN; Dugan WM; Parashos PJ; Triplett WC; Minnick DJ; Fry MW
Prog Clin Biol Res; 1986; 216():407-16. PubMed ID: 3523534
[No Abstract] [Full Text] [Related]
14. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Kwong WJ; Parasuraman TV
Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
[TBL] [Abstract][Full Text] [Related]
16. Fighting nausea in the '90s: more and better anti-emetics can help.
Saphir A
J Natl Cancer Inst; 1997 Sep; 89(17):1252-5. PubMed ID: 9293911
[No Abstract] [Full Text] [Related]
17. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
18. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
19. Prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Aapro MS
Ariz Med; 1981 Nov; 38(11):843-5. PubMed ID: 6274276
[No Abstract] [Full Text] [Related]
20. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
